<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2022v4.1">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2023-03-08T14:44:18-06:00</ReturnTs>
    <TaxPeriodEndDt>2022-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>133632313</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>TOBIN &amp; COMPANY CPA'S</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>2500 WESTCHESTER AVENUE</AddressLine1Txt>
        <CityNm>PURCHASE</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10577</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2022-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>853259676</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>HUNTERS CMT4B3 RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>HUNT</BusinessNameControlTxt>
      <PhoneNum>9145898047</PhoneNum>
      <USAddress>
        <AddressLine1Txt>77 GARDEN RD</AddressLine1Txt>
        <CityNm>SCARSDALE</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10583</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>IRIS SCHULTZ</PersonNm>
      <PersonTitleTxt>PRESIDENT</PersonTitleTxt>
      <PhoneNum>9145898047</PhoneNum>
      <SignatureDt>2023-03-07</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>IRIS</PersonFirstNm>
        <PersonLastNm>SCHULTZ</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>0</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PTIN>P00593418</PTIN>
      <PhoneNum>9148332200</PhoneNum>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>0</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2022</TaxYr>
    <BuildTS>2023-04-26 12:10:37Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="6">
    <IRS990 documentId="RetDoc1038000001" referenceDocumentId="RetDoc1044400001">
      <PrincipalOfficerNm>IRIS SCHULTZ</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>77 GARDEN ROAD</AddressLine1Txt>
        <CityNm>SCARSDALE</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10583</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>352665</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>0</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.CMT4B3RESEARCH.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>2020</FormationYr>
      <LegalDomicileStateCd>DE</LegalDomicileStateCd>
      <ActivityOrMissionDesc>TO FUND SCIENTIFIC RESEARCH LEADING TO THE DISCOVERY, DEVELOPMENT AND CLINICAL APPLICATIONS FOR THERAPEUTIC TREATMENTS AND CURES FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 4B3 (CMT 4B3), AND TO IMPROVE THE QUALITY OF LIFE FOR PEOPLE WITH CMT4B3.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>8</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>8</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <TotalVolunteersCnt>7</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>620436</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>348400</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>2</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>4265</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>0</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>0</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>620438</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>352665</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>70518</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>260263</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>0</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>0</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>6136</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>30061</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>46004</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>100579</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>306267</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>519859</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>46398</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>650515</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>692726</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>8881</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>19202</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>641634</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>673524</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>TO FUND SCIENTIFIC RESEARCH LEADING TO THE DISCOVERY, DEVELOPMENT, AND CLINICAL APPLICATIONS FOR THEREPEUTIC TREATMENTS AND CURES FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 4B3 (CMT 4B3), AND TO IMPROVE THE QUALITY OF LIFE FOR PEOPLE WITH CMT4B3.</MissionDesc>
      <SignificantNewProgramSrvcInd>0</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>0</SignificantChangeInd>
      <ExpenseAmt>275857</ExpenseAmt>
      <GrantAmt>260263</GrantAmt>
      <Desc>CMT4B3 AWARDS RESEARCH FELLOWSHIP AND GRANTS FOR RESEARCH ON CHARCOT-MARIE-TOOTH DISEASE TYPE 4B3. IT ALSO HOSTS BI-ANNUAL MEETINGS OF ALL RESEARCHERS RECEIVING ITS FUNDING AND ITS SCIENTIFIC ADVISORY BOARD TO PROMOTE KNOWLEDGE EXCHANGE AND SYNERGY. IT USES THE SERVICES OF ITS SCIENTIFIC ADVISORY BOARD TO CAREFULLY OVERSEE AND REVIEW THE SELECTION OF THE RECIPIENTS OF THE RESEARCH FUNDING. THE SAB EVALUATES EACH PROPOSAL BASED ON THE EXCELLENCE OF THE INVESTIGATOR, THE WORK PLAN AND THE PROPOSALS' ABILITY TO BE TRANSLATED INTO TREATMENTS FOR PEOPLE WITH CMT4B3. APPLICATIONS ARE REVIEWED ON A ROLLING BASIS. THE LAW FIRM OF KATTEN MUCHIN ROSENMAN, LLP WRITES THE GRANT AGREEMENT CONTRACTS WITH THESE RESEARCHERS, UNIVERSITIES, OR ACADEMIC INSTITUTIONS.THE BOARD MEMBERS, IRIS SCHULTZ AND ROBIN SCHULTZ, ATTEND THE YEARLY MEETING OF THE PERIPHERAL NERVE SOCIETY. ALL EXPENSES RELATED TO ATTENDING THE CONFERNCE ARE PERSONALLY COVERED BY THE BOARD MEMBERS. CMT4B3 IS LISTED AS A PATIENT RESOURCE OF THE PNS. ATTENDANCE AT THE PNS GIVES BOARD MEMBERS THE ABILITY TO MEET WITH AND EXCHANGE IDEAS WITH INTERNATIONAL RESERACHERS OF CMT AND CMT4B3.CMT4B3 MAINTAINS A WEBSITE FOR PATIENTS, THEIR FAMILIES AND MEDICAL PRACTITIONERS TO ASSIST IN UNDERSTANDING AND TREATING CHARCOT-MARIE-TOOTH DISEASE TYPE 4B3. THE WEBSITE CONTAINS LINKS TO OUR RESEARCH PROJECTS, A NEW PATIENT PORTAL TO JOIN OUR NEUROGENETICS REGISTRY AND THE ABILITY TO JOIN OUR NATURAL HISTORY STUDIES. CMT4B3 PRODUCES EDUCATIONAL MATERIALS DISSEMINATED AT CONFERENCES AND AT PUBLIC EVENTS TO RAISE AWARENESS. CMT4B3 MAINTAINS CLIENT MANAGEMENT SOFTWARE. IT RETAINS ACCOUNTING SERVICES. CMT4B3 FOUNDATION IS COMPOSED OF VOLUNTEERS WHO WORK FROM HOME AND DO NOT TAKE ANY SALARIES.</Desc>
      <TotalProgramServiceExpensesAmt>275857</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="RetDoc1039100001">1</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="RetDoc1234500001">1</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>0</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>0</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd>0</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
      <ConservationEasementsInd>0</ConservationEasementsInd>
      <CollectionsOfArtInd>0</CollectionsOfArtInd>
      <CreditCounselingInd>0</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>0</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd>0</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd>0</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd>0</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd>0</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd>0</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd>0</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd>0</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd>0</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>0</SchoolOperatingInd>
      <ForeignOfficeInd>0</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="RetDoc1040500001">1</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="RetDoc1040500001">1</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="RetDoc1040500001">0</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>0</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>0</FundraisingActivitiesInd>
      <GamingActivitiesInd>0</GamingActivitiesInd>
      <OperateHospitalInd>0</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="RetDoc1041900001">1</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="RetDoc1041900001">0</GrantsToIndividualsInd>
      <ScheduleJRequiredInd>0</ScheduleJRequiredInd>
      <TaxExemptBondsInd>0</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>0</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>0</PYExcessBenefitTransInd>
      <LoanOutstandingInd>0</LoanOutstandingInd>
      <GrantToRelatedPersonInd>0</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>0</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>0</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>0</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd>0</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>0</DeductibleArtContributionInd>
      <TerminateOperationsInd>0</TerminateOperationsInd>
      <PartialLiquidationInd>0</PartialLiquidationInd>
      <DisregardedEntityInd>0</DisregardedEntityInd>
      <RelatedEntityInd>0</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>0</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>0</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>0</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>1</ScheduleORequiredInd>
      <IRPDocumentCnt>2</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>1</BackupWthldComplianceInd>
      <EmployeeCnt>0</EmployeeCnt>
      <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>0</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>0</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>0</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>0</QuidProQuoContributionsInd>
      <Form8282PropertyDisposedOfInd>0</Form8282PropertyDisposedOfInd>
      <IndoorTanningServicesInd>0</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>0</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>8</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>8</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>1</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>0</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>0</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>0</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>0</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>0</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>0</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>1</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>1</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>0</OfficerMailingAddressInd>
      <LocalChaptersInd>0</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>1</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>1</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>1</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>1</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>0</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>1</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>0</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>0</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>0</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <PersonNm>IRIS SCHULTZ</PersonNm>
        <PhoneNum>9145898047</PhoneNum>
        <USAddress>
          <AddressLine1Txt>77 GARDEN RD</AddressLine1Txt>
          <CityNm>SCARSDALE</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10583</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <NoListedPersonsCompensatedInd>X</NoListedPersonsCompensatedInd>
      <Form990PartVIISectionAGrp>
        <PersonNm>AMY C SCHWARTZ</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LIANNE C CAPPO</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MANDEEP KAUR CHOHAN</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>0.50</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>LINDSAY ZAKEN</PersonNm>
        <TitleTxt>SECRETARY</TitleTxt>
        <AverageHoursPerWeekRt>1.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JARED CASDEN</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>5.00</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>IRIS SCHULTZ</PersonNm>
        <TitleTxt>PRESIDENT</TitleTxt>
        <AverageHoursPerWeekRt>45.00</AverageHoursPerWeekRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>BRETT SCHULTZ</PersonNm>
        <TitleTxt>VICE PRESIDENT</TitleTxt>
        <AverageHoursPerWeekRt>5.00</AverageHoursPerWeekRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ROBIN SCHULTZ</PersonNm>
        <TitleTxt>TREASURER</TitleTxt>
        <AverageHoursPerWeekRt>45.00</AverageHoursPerWeekRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>0</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>0</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>0</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>0</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>0</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>0</CompensationFromOtherSrcsInd>
      <CntrctRcvdGreaterThan100KCnt>0</CntrctRcvdGreaterThan100KCnt>
      <AllOtherContributionsAmt>348400</AllOtherContributionsAmt>
      <TotalContributionsAmt>348400</TotalContributionsAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>4265</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>4265</RelatedOrExemptFuncIncomeAmt>
      </InvestmentIncomeGrp>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>352665</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>4265</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>235417</TotalAmt>
        <ProgramServicesAmt>235417</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>24846</TotalAmt>
        <ProgramServicesAmt>24846</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <FeesForServicesManagementGrp>
        <TotalAmt>2152</TotalAmt>
        <ProgramServicesAmt>806</ProgramServicesAmt>
        <FundraisingAmt>1346</FundraisingAmt>
      </FeesForServicesManagementGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>8608</TotalAmt>
        <ManagementAndGeneralAmt>8608</ManagementAndGeneralAmt>
      </FeesForServicesAccountingGrp>
      <AdvertisingGrp>
        <TotalAmt>6028</TotalAmt>
        <ManagementAndGeneralAmt>5833</ManagementAndGeneralAmt>
        <FundraisingAmt>195</FundraisingAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>10187</TotalAmt>
        <ProgramServicesAmt>1029</ProgramServicesAmt>
        <ManagementAndGeneralAmt>7708</ManagementAndGeneralAmt>
        <FundraisingAmt>1450</FundraisingAmt>
      </OfficeExpensesGrp>
      <TravelGrp>
        <TotalAmt>4552</TotalAmt>
        <ProgramServicesAmt>4552</ProgramServicesAmt>
      </TravelGrp>
      <InsuranceGrp>
        <TotalAmt>850</TotalAmt>
        <ManagementAndGeneralAmt>587</ManagementAndGeneralAmt>
        <FundraisingAmt>263</FundraisingAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>RESEARCH EXPENSE</Desc>
        <TotalAmt>8832</TotalAmt>
        <ProgramServicesAmt>8832</ProgramServicesAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>CREDIT CARD PROCESSING</Desc>
        <TotalAmt>2755</TotalAmt>
        <ManagementAndGeneralAmt>1373</ManagementAndGeneralAmt>
        <FundraisingAmt>1382</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>SUPPLIES</Desc>
        <TotalAmt>855</TotalAmt>
        <FundraisingAmt>855</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>POSTAGE AND SHIPPING</Desc>
        <TotalAmt>645</TotalAmt>
        <FundraisingAmt>645</FundraisingAmt>
      </OtherExpensesGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>540</TotalAmt>
        <ProgramServicesAmt>375</ProgramServicesAmt>
        <ManagementAndGeneralAmt>165</ManagementAndGeneralAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>306267</TotalAmt>
        <ProgramServicesAmt>275857</ProgramServicesAmt>
        <ManagementAndGeneralAmt>24274</ManagementAndGeneralAmt>
        <FundraisingAmt>6136</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>611685</BOYAmt>
        <EOYAmt>209913</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <EOYAmt>451090</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <EOYAmt>5000</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>38830</BOYAmt>
        <EOYAmt>26723</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <TotalAssetsGrp>
        <BOYAmt>650515</BOYAmt>
        <EOYAmt>692726</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>8881</BOYAmt>
        <EOYAmt>19202</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>8881</BOYAmt>
        <EOYAmt>19202</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>631634</BOYAmt>
        <EOYAmt>673524</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>10000</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>641634</BOYAmt>
        <EOYAmt>673524</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>650515</BOYAmt>
        <EOYAmt>692726</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <InfoInScheduleOPartXIInd>X</InfoInScheduleOPartXIInd>
      <ReconcilationRevenueExpnssAmt>46398</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>-14507</NetUnrlzdGainsLossesInvstAmt>
      <OtherChangesInNetAssetsAmt>-1</OtherChangesInNetAssetsAmt>
      <InfoInScheduleOPartXIIInd>X</InfoInScheduleOPartXIIInd>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>1</AccountantCompileOrReviewInd>
      <AcctCompileOrReviewBasisGrp>
        <SeparateBasisFinclStmtInd>X</SeparateBasisFinclStmtInd>
      </AcctCompileOrReviewBasisGrp>
      <FSAuditedInd>0</FSAuditedInd>
      <AuditCommitteeInd>1</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>0</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="RetDoc1039100001">
      <PubliclySupportedOrg509a2Ind>X</PubliclySupportedOrg509a2Ind>
      <GiftsGrantsContrisRcvd509Grp>
        <CurrentTaxYearMinus2YearsAmt>111190</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>620436</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>347900</CurrentTaxYearAmt>
        <TotalAmt>1079526</TotalAmt>
      </GiftsGrantsContrisRcvd509Grp>
      <Total509Grp>
        <CurrentTaxYearMinus2YearsAmt>111190</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>620436</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>347900</CurrentTaxYearAmt>
        <TotalAmt>1079526</TotalAmt>
      </Total509Grp>
      <AmountsRcvdDsqlfyPersonGrp>
        <TotalAmt>0</TotalAmt>
      </AmountsRcvdDsqlfyPersonGrp>
      <SubstantialContributorsAmtGrp>
        <TotalAmt>0</TotalAmt>
      </SubstantialContributorsAmtGrp>
      <SubstAndDsqlfyPrsnsTotGrp>
        <TotalAmt>0</TotalAmt>
      </SubstAndDsqlfyPrsnsTotGrp>
      <PublicSupportTotal509Amt>1079526</PublicSupportTotal509Amt>
      <GrossInvestmentIncome509Grp>
        <CurrentTaxYearMinus1YearAmt>2</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>4265</CurrentTaxYearAmt>
        <TotalAmt>4267</TotalAmt>
      </GrossInvestmentIncome509Grp>
      <InvestmentIncomeAndUBTIGrp>
        <CurrentTaxYearMinus1YearAmt>2</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>4265</CurrentTaxYearAmt>
        <TotalAmt>4267</TotalAmt>
      </InvestmentIncomeAndUBTIGrp>
      <TotalSupportCalendarYearGrp>
        <CurrentTaxYearMinus2YearsAmt>111190</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>620438</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>352165</CurrentTaxYearAmt>
        <TotalAmt>1083793</TotalAmt>
      </TotalSupportCalendarYearGrp>
      <PublicSupportCY509Pct>0.99610</PublicSupportCY509Pct>
      <InvestmentIncomeCYPct>0.00390</InvestmentIncomeCYPct>
      <ThirtyThrPctSuprtTestsCY509Ind>X</ThirtyThrPctSuprtTestsCY509Ind>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleF documentId="RetDoc1040500001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <TypeOfActivitiesConductedTxt>GRANT MAKING</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH GRANTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>14179</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>NORTH AMERICA</RegionTxt>
        <TypeOfActivitiesConductedTxt>GRANT MAKING</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>RESEARCH GRANTS</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>10667</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>0</SubtotalEmployeesCnt>
      <ContinuationTotalOfficeCnt>0</ContinuationTotalOfficeCnt>
      <ContinuationTotalEmployeeCnt>0</ContinuationTotalEmployeeCnt>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <SubtotalSpentAmt>24846</SubtotalSpentAmt>
      <ContinuationSpentAmt>0</ContinuationSpentAmt>
      <TotalSpentAmt>24846</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND &amp; GREENLAND)</RegionTxt>
        <PurposeOfGrantTxt>INVESTIGATING CMT4B3</PurposeOfGrantTxt>
        <CashGrantAmt>14179</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE</MannerOfCashDisbursementTxt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>FMV</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>NORTH AMERICA</RegionTxt>
        <PurposeOfGrantTxt>INVESTIGATING CMT4B3</PurposeOfGrantTxt>
        <CashGrantAmt>10667</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE</MannerOfCashDisbursementTxt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>FMV</ValuationMethodUsedDesc>
      </GrantsToOrgOutsideUSGrp>
      <TransferToForeignCorpInd>0</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>0</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>0</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>0</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>0</ForeignPartnershipInd>
      <BoycottCountriesInd>0</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>CMT4B3 REQUIRES (BY CONTRACT) PERIOD PROGRESS REPORTS ON THE FUNDED RESEARCH. THE PROGRESS REPORTS ARE REVIEWED BY THE SCIENTIFIC ADVISORY BOARD AND THE BOARD OF DIRECTORS. ITS GRANT AGREEMENT CONTRACTS ALSO INCLUDE A FULL RESEARCH PLAN WITH BUDGETS AND DELIVERABLES. CMT4B3 USES THE SERVICES OF ITS SCIENTIFIC ADVISORY BOARD WHEN REVIEWING INTERNATIONAL GRANTEES, TO CAREFULLY OVERSEE AND REVIEW THE SELECTION OF THE RECIPIENTS OF THE RESEARCH FUNDING. THE SAB EVALUATES EACH PROPOSAL BASED ON THE EXCELLENCE OF THE INTERNATIONAL INVESTIGATOR, THE WORK PLAN, AND THE PROPOSALS' ABILITY TO BE TRANSLATED INTO TREATMENTS FOR PEOPLE. WITH CMT4B3. APPLICATIONS ARE REVIEWED ON A ROLLING BASIS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III ACCOUNTING METHOD:</FormAndLineReferenceDesc>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SUPPLEMENTAL INFORMATION (PART V, OTHER)</FormAndLineReferenceDesc>
        <ExplanationTxt>PROFESSOR HENRY HOULDEN, UNIVERSITY COLLEGE LONDON, QUEENS SQUARE WE HAVE DETAILED CLINICAL NOTES AND MRI'S FROM NEW YORK, UK, AND SPANISH CMT4B3 FAMILIES. TO UNDERSTAND DISEASE ONSET AND PROGRESSION WE PLAN TO EXPAND THE KNOWLEDGE OF THE NATURAL HISTORY OF CMT4B3 AND OBTAIN CLINICAL FEATURES, CLINICAL SCALES AND SERIAL MRI SCANS AS MARKERS OF CMT4B3 PROGRESSION, FROM A FURTHER EIGHT FAMILIES WITH BIALLELIC SBF1 MUTATIONS WITH A RANGE OF REPORTED DISEASE SEVERITIES. IDEALLY THIS WOULD BE CARRIED OUT OVER 3 YEARS TO UNDERSTAND PROGRESSION BUT WE HAVE SUBMITTED THIS PROJECT FOR 18 MONTHS AS AN INITIAL PERIOD. WE HAVE NOT REQUESTED FUNDING FOR MRI'S, NEUROPHYSIOLOGY OR CLINICAL ASSESSMENT OF PATIENTS BUT WE WISH TO OBTAIN (WITH PATIENT/FAMILY PERMISSION) MRI DETAILS, NEUROPHYSIOLOGY OR CLINICAL ASSESSMENTS (IDEALLY CMT RATING SCALES) FOR THE NATURAL HISTORY THAT ARE PART OF THEIR CLINICAL CARE IN THEIR COUNTRY. PROFESSOR JIM DOWLING - SICK KIDS HOSPITAL - DRUG DISCOVERY FOR CMT4B3 USING ZEBRAFISH MODEL PATIENTS WITH CMT4B3 HAVE BIALLELIC, LOSS OF EXPRESSION/FUNCTION MUTATIONS IN MTMR5. USING CRISPR/CAS9 GENE EDITING, WE WILL ACCURATELY MODEL THE DISEASE BY CREATING BIALLELIC NULL MUTATIONS IN MTMR5. WE WILL CHARACTERIZE THE RESULTING PHENOTYPE OF THESE MTMR5 "KNOCKOUT" FISH, WITH AN EMPHASIS ON IDENTIFYING PHENOTYPES SUITABLE FOR DRUG SCREENING.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleI documentId="RetDoc1041900001">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NEUMOURS CHILDREN HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1600 ROCKLAND ROAD</AddressLine1Txt>
          <CityNm>WILMINGTON</CityNm>
          <StateAbbreviationCd>DE</StateAbbreviationCd>
          <ZIPCd>19803</ZIPCd>
        </USAddress>
        <CashGrantAmt>32000</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>PROJECT:MOTOR NEURON DYSFUNCTION</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1320 S DIXIE HIGHWAY</AddressLine1Txt>
          <CityNm>MIAMI</CityNm>
          <StateAbbreviationCd>FL</StateAbbreviationCd>
          <ZIPCd>33146</ZIPCd>
        </USAddress>
        <CashGrantAmt>45364</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>MTMRS MINIGENE CONSTRUCTIONS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE JACKSON LABORATORY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>600 MAIN STREET</AddressLine1Txt>
          <CityNm>BAR HARBOR</CityNm>
          <StateAbbreviationCd>ME</StateAbbreviationCd>
          <ZIPCd>04609</ZIPCd>
        </USAddress>
        <CashGrantAmt>26435</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>EXAMINING SBF1 IN MUTANT MICE FOR RELEVANT PHENOTYPES</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NATIONWIDE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>700 CHILDRENS DRIVE</AddressLine1Txt>
          <CityNm>COLUMBUS</CityNm>
          <StateAbbreviationCd>OH</StateAbbreviationCd>
          <ZIPCd>43205</ZIPCd>
        </USAddress>
        <CashGrantAmt>31234</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF SPLIT-VECTOR AAV APPROACHES FOR CMT4B3</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1320 S DIXIE HIGHWAY</AddressLine1Txt>
          <CityNm>MIAMI</CityNm>
          <StateAbbreviationCd>FL</StateAbbreviationCd>
          <ZIPCd>33146</ZIPCd>
        </USAddress>
        <CashGrantAmt>100384</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>DEVELOPING HUMAN PLATFORMS FOR THERAPY DEVELOPMENTS</PurposeOfGrantTxt>
      </RecipientTable>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION REQUIRES BY CONTRACT PERIOD PROGRESS REPORTS ON THE FUNDED RESEARCH. THE PROGRESS REPORTS ARE REVIEWED BY THE SCIENTIFIC ADVISORY BOARD AND THE BOARD OF DIRECTORS. ITS GRANT AGREEMENT CONTRACTS ALSO INCLUDE A FULL RESEARCH PLAN WITH BUDGETS AND DELIVERABLES. THE FOUNDATION USES THE SERVICES OF ITS SCIENTIFIC ADVISORY BOARD WHEN REVIEWING DOMESTIC GRANTEES, TO CAREFULLY OVERSEE AND REVIEW THE SELECTION OF THE RECIPIENTS OF THE RESEARCH FUNDING. THE SAB EVALUATES EACH PROPOSAL BASED ON THE EXCELLENCE OF THE DOMESTIC INVESTIGATOR, THE WORK PLAN AND THE PROPOSALS ABILITY TO BE TRANSLATED INTO TREATMENTS FOR PEOPLE WITH CMT4B3. APPLICATIONS ARE REVIEWED ON A ROLLING BASIS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>ADDITIONAL INFORMATION FOR SCHEDULE I</FormAndLineReferenceDesc>
        <ExplanationTxt>SPECIFIC AIMS OF THE GRANTS - DR. MATTHEW BUTCHBACH, NEUMOURS ALFRED 1 DUPONT CHILDREN'S HOSPITAL PURPOSE: TO ESTABLISH AND TO CHARACTERIZE CELL CULTURE AND MOUSE MODELS FOR CMT4B3. DR. STEPHAN ZUCHNER, UNIVERSITY OF MIAMI PURPOSE: MTMR5 MINIGENE CONSTRUCTION AND VALIDATION TO CURE CMT4B3. AIM 1: CONSTRUCT UP TO 20 CANDIDATE MTMR5 MINIGENE IN SILICO MODELS, BASED ON STRUCTURAL, CONSERVATION, AND OTHER CONSIDERATIONS AIM 2: TEST THESE MODELS IN DIFFERENT PROTEIN MODELING PROGRAMS AND ITERATIVELY IMPROVE UPON THEIR DESIGN. SELECT THE 5 BEST MODELS. AIM 3: SYNTHESIZE THE 5 BEST MTMR5 MODELS, CREATE VECTORS FOR IN VITRO CELL TRANSFECTION OF HEK293 OR SIMILAR CELL FOR EVALUATING TOXICITY. MARIO SAPORTA - UNIVERSITY OF MIAMI PURPOSE: DEVELOPING HUMAN PLATFORMS FOR THERAPY DEVELOPMENT FOR CMT4B3 - PATIENT-DERIVED MOTOR NEURONS, SENSORY NEURONS AND GLIAL CELLS IN 3D CULTURE SYSTEMS SAPORTA'S LABORATORY HAS SPENT THE LAST FIVE YEARS DEVELOPING HUMAN IN VITRO CELLULAR MODELS TO STUDY AXONAL PHENOTYPES IN INHERITED PERIPHERAL NEUROPATHIES (CHARCOT-MARIE-TOOTH DISEASE, CMT). HE WILL USE THIS SYSTEM TO INVESTIGATE DISEASE PHENOTYPES IN HUMAN CMT4B3 PATIENT-DERIVED MOTOR NEURONS AND TO EXPAND THIS PLATFORM TO ALSO INCLUDE SENSORY NEURONS AND SCHWANN CELLS, MAJOR CELL TYPES INVOLVED IN THE BIOLOGY OF CMT4B3. OUR GOAL IS TO USE THESE RESOURCES TO VALIDATE GENE REPLACEMENT THERAPY STRATEGIES AND IDENTIFY SMALL MOLECULE CANDIDATES USING HIGH CONTENT SCREENING TO TREAT CMT4B3. SCOTT HARPER, NATIONWIDE CHILDREN'S HOSPITAL: DEVELOPMENT OF SPLIT-VECTOR AAV APPROACHES FOR CMT4B3 PURPOSE: DEVELOP 3 DIFFERENT SPLIT-VECTOR AAV SYSTEMS TO ACHIEVE RECOMBINATION OF THE SBF1 GENE IN MICE. ROBERT BURGESS - JACKSON LABORATORY: PURPOSE: EXAMINING SBF1 MUTANT MICE FOR CMT4B3 RELEVANT PHENOTYPES AIM 1: DETAILED CHARACTERIZATION OF THE SBF1-/- MICE FOR DISEASE-RELEVANT PHENOTYPES. THESE ANALYSES WILL BE PERFORMED AT 6 MONTHS OF AGE AND WILL INDICATE IF DISEASE-RELEVANT DEFICITS ARE PRESENT IN THE MICE, WHICH COULD PROVIDE IMPORTANT OUTCOMES FOR EVENTUAL THERAPEUTIC TESTING. AIM 2: GENE EXPRESSION ANALYSIS OF SBF1-/- MICE. GENE EXPRESSION SIGNATURES CAN PROVIDE INFORMATION ABOUT POSSIBLE DISEASE MECHANISMS, SUGGEST THERAPEUTIC STRATEGIES, AND IDENTIFY "ENDOPHENOTYPES" THAT CAN BE USED TO SEE IF POTENTIAL THERAPIES ARE INDEED ALTERING THE PATHOPHYSIOLOGY. THESE STUDIES WILL DETERMINE WHETHER THE SBF1-/- MICE ARE A SUITABLE PRECLINICAL MODEL OF CMT4B3 AND MAY ALSO IDENTIFY NEW DISEASE MECHANISMS, THERAPEUTIC TARGETS, AND ENDOPHENOTYPES.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleO documentId="RetDoc1044400001">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION A, LINE 2</FormAndLineReferenceDesc>
        <ExplanationTxt>IRIS AND BRETT SCHULTZ ARE MARRIED ROBIN SCHULTZ IS BRETT'S MOTHER</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 11B</FormAndLineReferenceDesc>
        <ExplanationTxt>HUNTERS CMT4B3 RESEARCH FOUNDATION PROVIDES AND ELECTRONIC COPY OF THE DRAFT FORM 990 TO ALL BOARD MEMBERS PRIOR TO FILING, AS WELL AS THE FINAL COPY FILED WITH THE IRS TO BE KEPT IN THEIR BOARD NOTEBOOK.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION B, LINE 12C</FormAndLineReferenceDesc>
        <ExplanationTxt>ALL BOARD MEMBERS AND OFFICERS FILL OUT AND SIGN A DOCUMENT ASSERTING THEY HAVE READ AND UNDERSTOOD THE CONFILCT OF INTEREST POLICY AND DISCLOSE THEIR COMPLIANCE. THE CONFLICT OF INTEREST POLICY IS REVIEWED AND UPDATED ANNUALLY. THE ORGANIZATION HAS AN ANNUAL WORKSHOP FOR ALL BOARD MEMBERS. THE BOARD CHAIRMAN AND CEO REVIEW AND MONITOR THE CONFLICT OF INTEREST DISCLOSURES. IF A CONFLICT OF INTEREST IS IDENTIFIED, THE RESPONSIBLE PERSON SHALL REFRAIN FROM ANY ACTION THAT MAY AFFECT CMT4B3'S PARTICIPATION IN SUCH CONTRACT OF TRANSACTION.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, SECTION C, LINE 19</FormAndLineReferenceDesc>
        <ExplanationTxt>COPIES ARE SENT UPON WRITTEN REQUEST.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XI, LINE 9:</FormAndLineReferenceDesc>
        <ExplanationTxt>ROUNDING -1.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XII, LINE 2C</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION HAS NOT CHANGED ITS OVERSIGHT PROCESS DURING THE YEAR.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>
